

REMARKS

The Examiner's Office Action of September 1, 2004 has been received and its contents reviewed. Applicants would like to thank the Examiner for the consideration given to the above-identified application, for indicating the allowance of claim 21, and also for indicating the allowance of claim 20 if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

By this Amendment, claims 4-8 and 17-19 have been amended, claims 10 and 20 have been canceled, and new claims 22-28 have been added. Claims 1-3, 9 and 11-16 have previously been cancelled. Accordingly, claims 4-8, 17-19 and 21-28 are pending for consideration, of which claims 17, 18, 21-23 and 25-28, are independent. Applicants respectfully request reconsideration and allowance of all the pending claims.

Starting on page 2 of the Office Action, claims 4-8, 10, 17 and 19 rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent No. 4,469,527 to Sugano et al. in view of U.S. Patent No. 5,010,037 to Lin et al.. Also, claims 4-8, 10, 17 and 19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sugano in view of Lin as applied to claims 4-8, 10, 17 and 19 above, and further in view of U.S. Patent No. 5,930,608 to Yamazaki et al. (hereinafter Yamazaki). Additionally, claims 4-8, 10 and 17-19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sugano in view of Lin et al. as applied to claims 4-8, 10 and 17-19 above, and further in view of U.S. Patent No. 5,830,775 to Maa et al. In view of the amendments above and the comments that follow, Applicants respectfully request reconsideration and withdrawal of the rejection.

By the foregoing amendment, independent claims 17 and 18 have been amended to include the subject matter of claim 20, indicated in the Office Action as being allowable. Accordingly, Applicants respectfully submit that amended claims 17 and 18 are now allowable.

Applicants respectfully submit that newly added claim 22 corresponds to the allowable claim 21 with the feature directed to "a dosage of said nonmetal element" being changed to "a distribution of said nonmetal element." Newly added independent claim 23 corresponds to allowable claim 21 with the feature directed to "a dosage of said nonmetal element" being changed to "a concentration of said nonmetal element." Applicants respectfully submit that claims 22 and 23 are allowable.


Applicants respectfully submit that newly added claim 25 corresponds to claim 17 with the feature of "a dosage of said nonmetal element" being changed to "a distribution of said nonmetal element." Newly added claim 26 corresponds to claim 17 with the feature "a dosage of said nonmetal element" being changed to "a concentration of said nonmetal element". Applicants respectfully submit that claims 25 and 26 are allowable.

Applicants respectfully submit that newly added claim 27 corresponds to claim 18 with the feature directed to "a dosage of said nonmetal element" being changed to "a distribution of said nonmetal element.", Newly added claim 28 corresponds to claim 18 with the feature directed to "a dosage of said nonmetal element" being changed to "a concentration of said nonmetal element". Applicants respectfully submit that claims 27 and 28 are allowable.

In view of the amendments and arguments set forth above, Applicants respectfully request reconsideration and withdrawal of all the pending rejections.

While the present application is now believed to be in condition for allowance, should the Examiner find some issue to remain unresolved, or should any new issues arise which could be eliminated through discussions with Applicants' representative, then the Examiner is invited to contact the undersigned by telephone in order that the further prosecution of this application can thereby be expedited.

Respectfully submitted,



Thomas W. Cole

Registration No. 29,290

NIXON PEABODY LLP
401 9th Street, N.W.
Washington, DC 20004
Telephone: (202) 585-8000
Facsimile: (303) 585-8080
DRS/BCO